



**Superior  
Health Council**

# **VACCINATION STRATEGY AGAINST COVID-19 IN BELGIUM**

**JULY 2020  
SHC № 9597**



**.be**

## **COPYRIGHT**

Federal Public Service Health, Food Chain Safety  
and Environment

### **Superior Health Council**

Place Victor Horta 40 bte 10  
B-1060 Bruxelles

Tel.: 02/524 97 97

E-mail: [info.hgr-css@health.belgium.be](mailto:info.hgr-css@health.belgium.be)

All rights reserved.

Please cite this document as follows:

Superior Health Council. Vaccination strategy against Covid-19  
in Belgium. Brussels: SHC; 2020. Report 9597

Public advisory reports as well as booklets may be consulted  
in full on the Superior Health Council website:

[www.css-hgr.be](http://www.css-hgr.be)

This publication cannot be sold.



## **ADVISORY REPORT OF THE SUPERIOR HEALTH COUNCIL no. 9597**

### **Vaccination strategy against Covid-19 in Belgium**

In this scientific advisory report, which offers guidance to public health policy-makers, the Superior Health Council of Belgium provides recommendations on risk groups in the context of vaccination against Covid-19 for the Belgian population.

This report aims at providing policy-makers with specific recommendations on risk groups, priority groups and an estimation of number of vaccines needed if a vaccine against Covid-19 becomes available.

This version was validated by the Board on  
1 July 2020

Amended version on  
7 July 2020

## **I INTRODUCTION AND ISSUE**

The development of a vaccine against Covid-19 is rapidly evolving. A few vaccines candidates are already in clinical evaluation and lots of them are in the pre-clinical stage.

As of 8 June 2020, the following vaccines have entered in clinical development:  
<https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker>

Belgium is participating in a EU joint procurement for COVID-19 vaccine to secure access to it. In order to define the needed doses, all member states are asked to define their target population for vaccination.

On 6 May 2020 and 21 May 2020 the Superior Health Council (SHC) received a request from Dr Paul Pardon, the president of the Risk Management Group (RMG), to define the priority groups and number of doses needed for vaccination against Covid-19.

This advisory report will provide recommendations on the risk groups and an estimation of the number of doses needed if a vaccine will be available.

## II RECOMMENDATIONS

The SHC recommends to prioritize the following groups for vaccination against Covid-19 based on the available data and statistical evidence:

- **All workers in the health care sector** to secure their health and a working health care sector during a potential next COVID-19 wave or pandemic;
- **All people above 65 years of age;**
- Patients between 45 and 65 years with the following comorbidities which are at risk for developing severe COVID-19: **obesity, diabetes, hypertension, chronic cardiovascular, lung, kidney and liver diseases and haematological malignancies up to 5 years from diagnosis and all recent solid cancers (or recent cancer treatments).**

Further prioritisation inside the above groups may be considered if a limited amount of vaccine is available.

This recommendation can be changed according to new data and information on immunogenicity of the type of vaccine(s) that will be available. For instance, we will further follow data regarding pregnant woman, other immunocompromised patients as well as the impact of socio-economical and ethnic background.

Furthermore, the impact and the need of vaccination against Covid-19 to manage an outbreak will be evaluated when more information will be available on the new vaccine(s).

An estimation of around 4 000 000 number of people are in the risk and priority groups for vaccination against Covid-19 in Belgium (Chapter 4.4).

We can assume that at least 20 and 30 % in the priority and risk groups will refuse vaccination (Chapter 4.5).

### Keywords and MeSH *descriptor terms*<sup>1</sup>

MeSH terms*	Keywords	Sleutelwoorden	Mots clés	Schlüsselwörter
Coronavirus infections*/immunology	Coronavirus			
	Covid-19			
	Vaccination			
Pandemics*	Comorbidity			
Coronavirus infections*/prevention & control	Risk group			
	Prevention			
Viral vaccines/administration & dosage	Priority group			
Humans	Humans			

MeSH (Medical Subject Headings) is the NLM (National Library of Medicine) controlled vocabulary thesaurus used for indexing articles for PubMed: <http://www.ncbi.nlm.nih.gov/mesh>.

<sup>1</sup> The Council wishes to clarify that the MeSH terms and keywords are used for referencing purposes as well as to provide an easy definition of the scope of the advisory report. For more information, see the section entitled "methodology".

### III METHODOLOGY

After analysing the request, the Board and, when appropriate, the Chair of the area Vaccination identified the necessary fields of expertise. An *ad hoc* working group was then set up which included experts in epidemiology, vaccinology and infectiology. The experts of this working group provided a general and an *ad hoc* declaration of interests and the Committee on Deontology assessed the potential risk of conflicts of interest.

This advisory report is based on analyses of Belgian data on COVID-19, scientific literature published in both scientific journals on European cases and reports from national and international organisations competent in this field, as well as on the opinion of the experts.

Once the advisory report was endorsed by the Belgian NITAG, it was ultimately validated by the Board.

### IV ELABORATION AND ARGUMENTATION

#### List of abbreviations used


Covid-19	Coronavirus Disease 2019
ICU	Intensive Care Unit
NITAG	National Immunization Technical Advisory Group
RMG	Risk Management Group
SHC	Superior Health Council
WHO	World Health Organisation

#### 1 Risk factors for severe Covid-19 hospitalisations in Belgium

The analyses are based on 2 major hospital endpoints: ICU admission and mortality during hospital stay for Covid-19 patients


##### 1.1 Age distribution of ICU admission and mortality (data from Sciensano, COVID-19 weekly report, 29 May 2020)

##### 1.1.1 *Proportion of ICU admissions by age group*



Half of the people on admitted in ICU were older than 65 years old.

### 1.1.2 Number of deaths by age group



Along all COVID-19 hospital deaths, less than 1 % were younger than 45 years old and 5 % were between 45 - 64 years old.

In summary, 50 % of the people admitted in ICU for COVID-19 and more than 90 % of the people dying from COVID-19 were older than 65 yrs.

### 1.2 Comorbidities in COVID-19 patients admitted in ICU and deceased (< 65 yrs old)

From 14 March 2020 on, all Belgian hospitals have, on a voluntarily basis, been invited by Sciensano to collect individual data on hospitalized patients with a confirmed COVID-19 infection, in order to identify risk factors for severe complications and to study hospitalized patient outcomes. The collected data include information on socio-demographic characteristics, comorbidities, admission in intensive care unit (ICU), final outcome (dead or discharged alive) and other information on clinical course and treatment. As of 24 May 2020 data were reported for 72 % of all known COVID-19 laboratory-confirmed admitted patients.

0 - 64 years			
	patients discharged alive (N = 3719)	deceased patients (N = 199)	ICU admissions (any outcome) (N = 568)
Comorbidity	%	%	%
Hypertension	20 %	34 %	35 %
Diabetics	13 %	23 %	21 %
Chronic renal failure	3 %	16 %	6 %
Chronic liver disease	2 %	11 %	3 %
Chronic lung disease	10 %	22 %	12 %
Chronic neurological disease	0 %	0 %	0 %
Cognitive illness	2 %	10 %	2 %

<b>Immunodeficiency (incl HIV)</b>	3 %	9 %	4 %
<b>Malign tumor</b>	3 %	14 %	3 %
<b>Blood cancer</b>	1 %	2 %	2 %
<b>Obesity</b>	7 %	10 %	11 %
<b>Number of comorbidities</b>	%	%	%
<b>0</b>	53 %	19 %	35 %
<b>&gt;= 1</b>	47 %	82 %	65 %

The descriptive data from 3918 patients hospitalized between 29 February and 10 May indicate that more than 80 % of the hospitalised patients younger than 65 years old who died, and 65 % of those admitted in ICU from Covid-19 presented at least 1 comorbidity.

#### 1.2.1 *Association between comorbidities and ICU admission and hospital mortality (< 65 yrs old), multivariate analysis*

A multivariable Cox proportional hazards model estimated from these data time to two endpoints: ICU admission and vital outcome (discharged alive vs death).

These analyses showed that among persons aged younger than 65 years, the risk of in-hospital death was significantly higher among persons with the following comorbidities: obesity, solid cancer, chronic liver disease, chronic lung disease, chronic kidney disease and cognitive disorders.

Furthermore among persons aged younger than 65 years, the risk of admission to ICU was significantly higher among persons with obesity or diabetes, and borderline significantly higher with cardiovascular comorbidity and high blood pressure.

## 2 Risk factors for developing severe Covid-19: international publications

- ECDC reported the following underlying health conditions among patients with COVID-19 and admitted to ICU: hypertension, diabetes, cardiovascular disease, chronic respiratory disease, immune compromised status, cancer and obesity. These proportions should be seen in light of the prevalence of these conditions in the underlying populations and cannot be interpreted directly as a risk factor.
- In a UK study from Docherty et al., 20 133 patients in hospital with Covid-19 were enrolled in a prospective observational cohort study. The risk factors defined by this study were chronic cardiac disease, chronic non-asthmatic pulmonary disease, chronic kidney disease, obesity, chronic neurological disorder (such as stroke), dementia, malignancy, and liver disease were also associated with increased hospital mortality (Docherty et al., 2020).
- Cecconi et al. studied 239 patients admitted in the hospital with Covid-19. 66.5 % had at least one coexisting medical condition. Hypertension (50.2 %), diabetes type 2 (21.8 %), coronary heart disease (CHD, 16.7 %), atrial fibrillation (11.3 %), active neoplasia (9.6 %) chronic obstructive pulmonary disease (9.2 %), and chronic kidney disease (8.4 %) were the most common comorbidities. Among those, only coexisting chronic heart disease was statistically significant predictor of clinical deterioration (ICU transfer or death) in hospitalized Covid-19 patients, as well as advanced age but not body mass index (Cecconi et al., 2020).



- The openSAFELY collaborative looked at factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. Most comorbidities were associated with higher risk of COVID-19 hospital death, including diabetes, asthma, respiratory disease, chronic heart disease, liver disease, stroke/dementia, other neurological diseases, reduced kidney function, autoimmune diseases (rheumatoid arthritis, lupus or psoriasis) and other immunosuppressive conditions.  
Those with a history of haematological malignancy were at > 3-fold increased risk up to 5 years from diagnosis, and nearly double the risk thereafter. For other cancers, risk increases were largely observed among those diagnosed in the last year.  
There was no association between hypertension and outcome (HR 0.95, 0.89 - 1.01). However, in sensitivity analyses, diagnosed hypertension was associated with slightly increased risk (HR 1.07, 1.00 - 1.15) while high blood pressure ( $\geq 140/90$  mmHg) at the most recent measurement was associated with lower risk (HR 0.61, 0.56 - 0.67).

### 3 Recommendation for risk groups and priority groups

The SHC recommends to prioritize the following groups for vaccination against Covid-19 based on the available data and statistical evidence:

- **All workers in the health care sector** to secure their health and a working health care sector during a potential next COVID-19 wave or pandemic;
- **All people above 65 years of age;**
- Patients between 45 and 65 years with the following comorbidities which are at risk for developing severe COVID-19: **obesity, diabetes, hypertension, chronic cardiovascular, lung, kidney and liver diseases and haematological malignancies up to 5 years from diagnosis and all recent solid cancers (or recent cancer treatments).**

Further prioritisation inside the above groups may be considered if a limited amount of vaccine is available.

This recommendation can be changed according to new data and information on immunogenicity of the type of vaccine(s) that will be available. For instance, we will further follow data regarding pregnant woman, other immunocompromised patients as well as the impact of socio-economical and ethnic background.

Furthermore, the impact and the need of vaccination against Covid-19 to manage an outbreak will be evaluated when more information will be available on the new vaccine(s).

### 4 Estimation of number people in Belgium in the recommended risk groups and priority groups

#### 4.1 Number of people over 65 years old

Based on the results of chapter 2 the SHC decided to include all persons above 65 year old as a risk group for vaccination against severe COVID-19 disease.

Belgium counted at the beginning of 2020 2 204 475 people over 65 years old (Statbel) (<https://bestat.statbel.fgov.be/bestat/crosstable.xhtml?view=161080d2-d411-4e40-9a0f-a27db5e2b6e1>).



#### 4.2 Estimated number of people with comorbidities at risk for developing severe COVID for people < 65 yrs old

The national health interview survey 2018 provides an estimation of the prevalence of a number of risk factors and comorbidities in the Belgian population.

In the general population aged **45 - 54 years**, the estimates for the prevalence of each of the comorbidity associated with increased risk of in-hospital death or ICU admission in COVID-19 patients are obesity (19 %), hypertension (17 %), diabetes (4 %) cardiovascular disease (4 %), chronic obstructive pulmonary disease (3 %), cancer (3 %), chronic kidney disease (1 %) and chronic liver disease (1 %).

In the general population aged **55 - 64 years**, the same prevalences are obesity (20 %), hypertension (28 %), diabetes (9 %) cardiovascular disease (10 %), chronic obstructive pulmonary disease (6 %), cancer (3 %), chronic kidney disease (0.3 %) and chronic liver disease (2 %).

Respectively 24 % and 28 % of the general population in the age groups 45 - 54 years and 55 - 64 years had at least one of the comorbidities that place them at increased risk for in-hospital death due to COVID-19.

Likewise, respectively 36 % and 50 % of the general population in the age group 45 - 54 years and the age group 55 - 64 years, had at least one of the comorbidities that place them at increased risk for ICU admission due to COVID-19.

Table: Estimated number of people with comorbidities at risk for developing severe COVID for people < 65 yrs old.

Prevalence in the general population	Estimation of number of people (N)	Risk factors for mortality (%)	Risk factors for ICU admission (%)	Persons with risk factors for ICU admission (N)
45 - 54y	1 571 828	24 %	36 %	565 858
55 - 64y	1 476 046	28 %	50 %	738 023
			<b>Total</b>	<b>1 303 881</b>

Sources: *Sciensano, SPMA mid-year population 2018-2019* ([https://s9xjb.wiv-isp.be/SASStoredProcess/quest?\\_program=/SPMA/SP/pop](https://s9xjb.wiv-isp.be/SASStoredProcess/quest?_program=/SPMA/SP/pop)) and Health Interview Survey 2018.

An estimated **1 303 881** persons < 65 years with comorbidities are at higher risk for developing severe COVID-19, based on risk factors for ICU admission.

#### 4.3 Estimation of number of people working in a the health care sector

To secure a working health care sector during a potential next COVID-19 wave or pandemic, the **SHC recommends to vaccinate all workers in the health care sector** including everybody working within a long term care facility.

In the table below an estimate is made based on various Belgian sources. As many data were not available in the short time for making this advice, some extrapolations have been done from one data source or one profession to another. In particular:

- We used estimates from 2018 INAMI/RIZIV per health profession when available, and 2019 STATAN data (SPF/FOD) of active professionals when other data were not available.
- When the proportion of registered professionals who are practising or the proportion of professionals above 65 years of age were not available, these have been

extrapolated between similar professions (e.g. from nurses to caregiver) from INAMI/RIZIV and/or SPF/FOD sources.

- The number of persons working per FTE has been extrapolated from the total workers to each category of staff, and from nursing homes of Wallonia to those of Flanders and Brussels.
- In hospitals and nursing homes, it has been estimated that all workers were < 65 years of age. The proportion of volunteers, interns and students has been extrapolated from Wallonia to the other regions.

Because the +65 year old working in the Health Care sector are included in the first group (Chapter 3) at risk, this age group was excluded from the estimates below.

Table: Estimated number of professionals working in health care services < 65 years of age.

Sectors and categories	Estimates	Source
Health care professionals: - Medical doctors, dentists, physiotherapists, pharmacists, paramedics - Nurses, midwives, caregivers, clinical psychologists, paramedics, technicians and assistants	111 223  224 656	INAMI/RIZIV 2018, 2017 data for age < 65 years  SPF/FOD STATAN 2019 (active professionals), <sup>§</sup> INAMI 2017 data for age*
Other (non-health) workers in nursing homes, including volunteers, internships and students	93 000	SPW, rapport bisannuel 2014 <sup>^</sup> and FTE; Belfius-MARA report 2015; extrapolated for the ratio persons/FTE and for Brussels
Other workers in hospitals: salaried non physicians, administrative and others	69 504	SPF/FOD FinHosp <sup>£</sup> ; extrapolated for the ratio persons/FTE on the total hospital staff
Other workers in other institutions	Unknown	
Informal carers	Unknown (20 % population > 50 yrs)	Share OECD study 2015
<b>Total</b>	<b>498 383</b>	

\*: [https://www.inami.fgov.be/SiteCollectionDocuments/statistique\\_2018\\_ss\\_proff\\_tableau1.pdf](https://www.inami.fgov.be/SiteCollectionDocuments/statistique_2018_ss_proff_tableau1.pdf)

§: <https://www.health.belgium.be/fr/sante/professions-de-sante/statistiques-et-planning>

^: <http://sante.wallonie.be/?q=node/4428>

£: [https://www.health.belgium.be/fr/sante/organisation-des-soins-de-sante/hopitaux/chiffres-et-rapports\\_\(FTE\)\\_and](https://www.health.belgium.be/fr/sante/organisation-des-soins-de-sante/hopitaux/chiffres-et-rapports_(FTE)_and)  
[https://www.health.belgium.be/fr/51-evolution-du-nombre-detp-payes-par-categorie-de-personnel\\_\(number\\_persons\)](https://www.health.belgium.be/fr/51-evolution-du-nombre-detp-payes-par-categorie-de-personnel_(number_persons))

Estimation of **498 383** people working in the Health Care Sector, not including non-health staff from other institutions and informal carers 50 - 64 years of age.

#### 4.4 Estimation of total number of people in the risk and priority groups for vaccination against Covid-19 in Belgium:

Priority groups	Number of people
Total number of +65 year old in Belgium (Chapter 4.1)	2 204 475
Estimation of 45 - 64 year olds with comorbidities at risk for developing severe Covid-19 in Belgium (Chapter 4.2)	1 303 881
Estimation of number of people working in the Health Care Sector in Belgium (Chapter 4.3)	498 383
<b>Total</b>	<b>4 006 739</b>

An estimation of 4 006 739 number of people are in the risk and priority groups for vaccination against Covid-19 in Belgium.

The number of needed doses will depend on the type of vaccine. If one or more doses are needed.

#### 4.5 Vaccination acceptance

Not everybody will accept this vaccination in the risk groups. If we look to seasonal flu vaccination, at least 30 % of the people > 65 yrs old were not vaccinated in the last influenza season in Belgium (62 % coverage in 2018). The vaccination acceptance of people < 65 yrs old with comorbidities is low, with influenza vaccine coverage at 27 % in 2018 in the 15 - 64 years of age (HIS 2018).<sup>2</sup>

For the health care workers, flu vaccination coverage is estimated at around 40 – 50 %, according to Belgian studies among GPs and more recently among 5 141 Belgian HCWs from 13 hospitals and 14 nursing homes (40 % in the hospitals and 45 % in the nursing homes) (Boey et al., 2018; KCE, 2011).

In addition, data from France suggest that 1/4 of people will refuse vaccination against Covid-19 (Coconel, Lancet 2020).

Therefore, we can assume that at least 20 and 30 % in the priority and risk groups will refuse vaccination.

### 5 Other target groups to be considered for vaccination against Covid-19?

The SHC provides recommendations for the general public health in Belgium. A list of risk groups is defined on who should be vaccinated in priority against Covid-19 based on the available data at this moment.

The SHC wants to address that there are other target groups who can be considered for vaccination against COVID-19 such as critical or essential service providers.

These other target groups are not addressed by the SHC in this report, this should be defined by other authorities than the SHC.

---

<sup>2</sup> Asthma, COPD, heart infarct, ischaemic heart, high blood pressure, diabetes or serious renal disorder.

## V REFERENCES

ECDC: Disease background of COVID-19:

<https://www.ecdc.europa.eu/en/2019-ncov-background-disease>

Boey L, Bral C, Roelants M, et al. Attitudes, beliefs, determinants and organisational barriers behind the low seasonal influenza vaccination uptake in healthcare workers - A cross-sectional survey. *Vaccine*. 2018;36(23):3351-3358.

Cecconi M, Piovani D, Brunetta E, et al. Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy. *J Clin Med*. 2020;9(5):E1548. Published 2020 May 20. doi:10.3390/jcm9051548.

COCONEL Group. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation [published online ahead of print, 2020 May 20]. *Lancet Infect Dis*. 2020;S1473-3099(20)30426-6.

COVID-19 Wekelijks epidemiologisch bulletin van 5 juni 2020 [Internet]. Sciensano; 2020 Jun p. 7–13. Available from: <https://covid-19.sciensano.be/nl/covid-19-epidemiologische-situatie>

Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ*. 2020;369:m1985. Published 2020 May 22. doi:10.1136/bmj.m1985.

KCE Reports 162B (2011): Vaccination contre la grippe saisonnière: groupes cibles prioritaires – partie I.

<https://kce.fgov.be/fr/vaccination-contre-la-grippe-saisonni%C3%A8re-groupes-cibles-prioritaires-%E2%80%93-partie-i>

OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. <https://www.medrxiv.org/content/10.1101/2020.05.06.20092999v1>

Van der Heyden J, Charafeddine R. Gezondheidsenquête 2018: Chronische ziekten en aandoeningen. Brussel, België: Sciensano. Rapportnummer: D/2019/14.440/36. Beschikbaar op: [www.gezondheidsenquête.be](http://www.gezondheidsenquête.be)

## VI COMPOSITION OF THE WORKING GROUP

The composition of the Committee and that of the Board as well as the list of experts appointed by Royal Decree are available on the following website: [About us](#).

All experts joined the working group *in a private capacity*. Their general declarations of interests as well as those of the members of the Committee and the Board can be viewed on the SHC website (site: [conflicts of interest](#)).

The following experts were involved in drawing up and endorsing this advisory report. The working group was chaired by **Yves VAN LAETHEM**; the scientific secretary was Veerle MERTENS.

<b>VAN LAETHEM Yves</b>	Infectiology, vaccinology	<i>CHU Saint-Pierre</i>
<b>MALI Stephanie</b>	Vaccine Spearheads coordinator	FAGG
<b>BOSSUYT Nathalie</b>	Epidemiology, infectiology	Sciensano
<b>HANQUET GERMAINE</b>	Epidemiology	KCE

The standing working group Vaccination (NITAG) has endorsed the advisory report. The NITAG was chaired by **Yves VAN LAETHEM**; the scientific secretary was Veerle MERTENS.

<b>BLUMENTAL Sophie</b>	Pediatrics, Infectiology	UKZKF
<b>CALLENS Steven</b>	Infectiology, Internal medicine	<i>UZ Gent</i>
<b>CHATZIS Olga</b>	Pediatric infectious disease	UCL
<b>DE LOOF Geert</b>	General medicine	BCFI
<b>FLAMAING Johan</b>	Geriatrics	<i>KU Leuven</i>
<b>GOETGHEBUER Tessa</b>	Infectiology	ULB
<b>LEROUX-ROELS Isabel</b>	Vaccinology, Microbiology	<i>UZ Gent</i>
<b>LEURIDAN Elke</b>	Vaccinology	<i>UAntwerpen</i>
<b>MANIEWSKI Ula</b>	Travel medicine, vaccinology	ITG
<b>MICHELIS Barbara</b>	General medicine	<i>UAntwerpen</i>
<b>PEETERMANS Willy</b>	Internal medicine, Infectiology, Vaccinology	<i>UZ Leuven</i>
<b>PELEMAN Renaat</b>	Internal Medicine, Infectiology	<i>UZ Gent</i>
<b>SOENTJENS Patrick</b>	Travel medicine	ITG
<b>SPODEN Julie</b>	General medicine	SSMG
<b>SWENNEN Béatrice</b>	Epidemiology, Vaccinology	ULB
<b>THEETEN Heidi</b>	Vaccinology	<i>UAntwerpen</i>
<b>TUERLINCKX David</b>	Pediatrics, vaccinology	<i>CHU UCL Namur</i>
<b>VAN DAMME Pierre</b>	Epidemiology, vaccinology	<i>UAntwerpen</i>
<b>VAN DER LINDEN Dimitri</b>	Pediatrics, infectiology	UCL
<b>VANDERMEULEN Corinne</b>	Epidemiology, vaccinology	<i>KU Leuven</i>
<b>VERHAEGEN Jan</b>	Microbiology, Bacteriology	<i>UZ Leuven</i>
<b>WAETERLOOS Geneviève</b>	Quality of vaccines and blood products	Sciensano
<b>WYNDHAM-THOMAS Chloé</b>	Infectiology	Sciensano

The following administrations and/or ministerial cabinets were heard:

CARRILLO SANTISTEVE  
Paloma

CORNELISSEN Tine

DAEMS Joël

DE SCHUTTER Iris

MAHIEU Romain

TOP Geert

VEKEMAN Veerle

WUILLAUME Françoise

ONE

*Kind en Gezin*

RIZIV

*Zorg en Gezondheid*

CCC

*Zorg en Gezondheid*

*Kind en Gezin*

FAGG

## About the Superior Health Council (SHC)

The Superior Health Council is a federal advisory body. Its secretariat is provided by the Federal Public Service Health, Food Chain Safety and Environment. It was founded in 1849 and provides scientific advisory reports on public health issues to the Ministers of Public Health and the Environment, their administration, and a few agencies. These advisory reports are drawn up on request or on the SHC's own initiative. The SHC aims at giving guidance to political decision-makers on public health matters. It does this on the basis of the most recent scientific knowledge.

Apart from its 25-member internal secretariat, the Council draws upon a vast network of over 500 experts (university professors, staff members of scientific institutions, stakeholders in the field, etc.), 300 of whom are appointed experts of the Council by Royal Decree. These experts meet in multidisciplinary working groups in order to write the advisory reports.

As an official body, the Superior Health Council takes the view that it is of key importance to guarantee that the scientific advisory reports it issues are neutral and impartial. In order to do so, it has provided itself with a structure, rules and procedures with which these requirements can be met efficiently at each stage of the coming into being of the advisory reports. The key stages in the latter process are: 1) the preliminary analysis of the request, 2) the appointing of the experts within the working groups, 3) the implementation of the procedures for managing potential conflicts of interest (based on the declaration of interest, the analysis of possible conflicts of interest, and a Committee on Professional Conduct) as well as the final endorsement of the advisory reports by the Board (ultimate decision-making body of the SHC, which consists of 30 members from the pool of appointed experts). This coherent set of procedures aims at allowing the SHC to issue advisory reports that are based on the highest level of scientific expertise available whilst maintaining all possible impartiality.

Once they have been endorsed by the Board, the advisory reports are sent to those who requested them as well as to the Minister of Public Health and are subsequently published on the SHC website ([www.hgr-css.be](http://www.hgr-css.be)). Some of them are also communicated to the press and to specific target groups (healthcare professionals, universities, politicians, consumer organisations, etc.).

In order to receive notification about the activities and publications of the SHC, please contact: [info.hgr-css@health.belgium.be](mailto:info.hgr-css@health.belgium.be).



**[www.css-hgr.be](http://www.css-hgr.be)**



This publication cannot be sold.



federal public service  
**HEALTH, FOOD CHAIN SAFETY  
AND ENVIRONMENT**